Trends in high-grade cervical lesions and cervical cancer screening in 5 states, 2008-2015

Clinical Infectious Diseases

Volumn 68, Issue 8, 2019, Pages 1282-1291

  Gargano, Julia Warner ^a   Park, Ina U ^b   Griffin, Marie R ^c   Niccolai, Linda M ^d   Powell, Melissa ^e   Bennett, Nancy M ^f   Johnson Jones, Michelle L ^a   Whitney, Erin ^g   Pemmaraju, Manideepthi ^c   Brackney, Monica ^d   Abdullah, Nasreen ^e   Scahill, Mary ^f   Dahl, Rebecca M ^a   Cleveland, Angela A ^a   Unger, Elizabeth R ^h   Markowitz, Lauri E ^a   Blankenship, Sheelah ^c   Allen, Stephanie ^c   Meek, James ^d   Higgins, Kyle ^d   Hadler, James ^d   Sosa, Lynn ⁱ   Saadeh, Kayla ^g   Williamson, Ashley ^g   Fink, Deanna ^g   Silverberg, Michael J ^j   Laing, Robert ^e   Schafer, Sean ^e   Oktapodas, Marina ^f   Felsen, Christina ^f   more..

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d YALE UNIVERSITY   (United States)

^e OREGON HEALTH AUTHORITY   (United States)

^f UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^g California Emerging Infections Program   (United States)

^h NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

ⁱ MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH   (United States)

^j KAISER PERMANENTE   (United States)

more..

Author keywords

cervical intraepithelial neoplasia; disease surveillance; human papillomavirus; vaccine impact

Indexed keywords

ADULT; AGE; ARTICLE; CANCER SCREENING; ETHNIC OR RACIAL ASPECTS; FEMALE; HUMAN; INSURANCE; PRIORITY JOURNAL; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; UTERINE CERVIX DISEASE; VACCINATION; YOUNG ADULT; ADENOCARCINOMA IN SITU; ADOLESCENT; EARLY CANCER DIAGNOSIS; UNITED STATES; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX TUMOR;

WART VIRUS VACCINE;

ADENOCARCINOMA IN SITU; ADOLESCENT; ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; EARLY DETECTION OF CANCER; FEMALE; HUMANS; PAPILLOMAVIRUS VACCINES; UNITED STATES; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 85064137950     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciy707     Document Type: Article

References (31)

1. Markowitz LE, Dunne EF, Saraiya M, et al., ; Centers for Disease Control and Prevention. Human papillomavirus vaccination: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2014; 63:1-30.
2. Dunne EF, Stokley S, Chen W, Zhou F. Human papillomavirus vaccination of females in a large health claims database in the United States, 2006-2012. J Adolesc Health 2015; 56:408-13.
3. Reagan-Steiner S, Yankey D, Jeyarajah J, et al., National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years-United States, 2015. MMWR Morb Mortal Wkly Rep 2016; 65:850-8.
4. Walker TY, Elam-Evans LD, Singleton JA, et al., National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years-United States, 2016. MMWR Morb Mortal Wkly Rep 2017; 66:874-82.
5. Williams WW, Lu PJ, O'Halloran A, et al., Surveillance of vaccination coverage among adult populations-United States, 2015. MMWR Surveill Summ 2017; 66:1-28.
6. Stokley S, Jeyarajah J, Yankey D, et al., Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014-United States. MMWR Morb Mortal Wkly Rep 2014; 63:620-4.
7. Markowitz LE, Hariri S, Lin C, et al., Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. J Infect Dis 2013; 208:385-93.
8. Markowitz LE, Liu G, Hariri S, Steinau M, Dunne EF, Unger ER. Prevalence of HPV after introduction of the vaccination program in the United States. Pediatrics 2016; 137:e20151968.
9. Oliver SE, Unger ER, Lewis R, et al., Prevalence of human papillomavirus among females after vaccine introduction-National Health and Nutrition Examination Survey, United States, 2003-2014. J Infect Dis 2017; 216:594-603.
10. Dunne EF, Naleway A, Smith N, et al., Reduction in human papillomavirus vaccine type prevalence among young women screened for cervical cancer in an integrated US Healthcare Delivery System in 2007 and 2012-2013. J Infect Dis 2015; 212:1970-5.
11. Bauer HM, Wright G, Chow J. Evidence of human papillomavirus vaccine effectiveness in reducing genital warts: An analysis of California public family planning administrative claims data, 2007-2010. Am J Public Health 2012; 102:833-5.
12. Flagg EW, Schwartz R, Weinstock H. Prevalence of anogenital warts among participants in private health plans in the United States, 2003-2010: Potential impact of human papillomavirus vaccination. Am J Public Health 2013; 103:1428-35.
13. Benard VB, Castle PE, Jenison SA, et al., ; New Mexico HPV Pap Registry Steering Committee. Population-based incidence rates of cervical intraepithelial neoplasia in the human papillomavirus vaccine era. JAMA Oncol 2017; 3:833-7.
14. Flagg EW, Torrone EA, Weinstock H. Ecological Association of human papillomavirus vaccination with cervical dysplasia prevalence in the United States, 2007-2014. Am J Public Health 2016; 106:2211-8.
15. Hariri S, Johnson ML, Bennett NM, et al., ; HPV-IMPACT Working Group. Population-based trends in high-grade cervical lesions in the early human papillomavirus vaccine era in the United States. Cancer 2015; 121:2775-81.
16. Bulletins-Gynecology ACoP. ACOG practice Bulletin no. 109: Cervical cytology screening. Obstet Gynecol 2009; 114:1409-20.
17. Moyer VA. Screening for cervical cancer: U. S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 156:880-91, w312.
18. Sawaya GF, Huchko MJ. Cervical cancer screening. Med Clin North Am 2017; 101:743-53.
19. Baldur-Felskov B, Dehlendorff C, Junge J, Munk C, Kjaer SK. Incidence of cervical lesions in Danish women before and after implementation of a national HPV vaccination program. Cancer Causes Control 2014; 25:915-22.
20. Brotherton JM, Fridman M, May CL, Chappell G, Saville AM, Gertig DM. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: An ecological study. Lancet 2011; 377:2085-92.
21. Brotherton JM, Gertig DM, May C, Chappell G, Saville M. HPV vaccine impact in Australian women: Ready for an HPV-based screening program. Med J Aust 2016; 204:184-184e1.
22. Ogilvie GS, Naus M, Money DM, et al., Reduction in cervical intraepithelial neoplasia in young women in British Columbia after introduction of the HPV vaccine: An ecological analysis. Int J Cancer 2015; 137:1931-7.
23. Hariri S, Markowitz LE, Bennett NM, et al., Monitoring effect of human papillomavirus vaccines in US population, emerging infections program, 2008-2012. Emerg Infect Dis 2015; 21:1557-61.
24. Watson M, Soman A, Flagg EW, et al., Surveillance of high-grade cervical cancer precursors (CIN III/AIS) in four population-based cancer registries, United States, 2009-2012. Prev Med 2017; 103:60-5.
25. Massad LS, Einstein MH, Huh WK, et al., 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis 2013; 17(Suppl 1):S1-S27.
26. ASCUS-LSIL Triage Study (ALTS) Group. A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. Am J Obstet Gynecol 2003; 188:1393-400.
27. Huh WK, Ault KA, Chelmow D, et al., Use of primary high-risk human papillomavirus testing for cervical cancer screening: Interim clinical guidance. J Low Genit Tract Dis 2015; 19:91-6.
28. United States Preventive Services Task Force. Draft recommendation statement, cervical cancer: Screening. Available at: Https://www. uspreventiveservicestaskforce. org/Page/Document/draft-recommendation-statement/cervical-cancer-screening2. Accessed 31 January 2018.
29. Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2016. Atlanta, GA: U. S. Department of Health and Human Services, 2017.
30. Petrosky E, Bocchini JA Jr, Hariri S, et al., ; Centers for Disease Control and Prevention. Use of 9-valent human papillomavirus (HPV) vaccine: Updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep 2015; 64:300-4.
31. Meites E, Kempe A, Markowitz LE. Use of a 2-dose schedule for human papillomavirus vaccination-updated recommendations of the advisory committee on immunization practices. Am J Transplant 2017; 17:834-7.